Eric Warren, Chief Commercial Officer of Mineralys Therapeutics, disposed of 7,437 shares of common stock on August 21 for a total of $193,188 under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026.
The transactions occurred at weighted-average prices of $25.9767 per share, with individual trades ranging from $25.82 to $26.15. The stock last traded at $26.34, reflecting a 78.7% gain over the prior 12 months and a market capitalization of $2.23 billion.
Warren’s sale followed the exercise of stock options for the same number of shares at $13.24 each, costing $98,465. The options vested 25% on the first anniversary of the grant date, with the remainder vesting in 36 equal monthly installments.
After the sale and option exercise, Warren holds 38,400 direct shares and retains 238,001 stock options. The company reported an adjusted net loss of $2.85 per share in the second quarter of 2026, wider than the $2.63 per share loss anticipated by analysts, as Mineralys continues to invest heavily in the potential commercialization of lorundrostat, its investigational blood pressure drug.
